In the Media

Michael Goldberg PhD '08 founded Surge Therapeutics, a company developing a hydrogel immunotherapy treatment aimed at reducing the risk of surgically-removed cancers returning, reports India Rice for Forbes. “Broadly speaking, immunotherapy is a range of cancer treatments that aim to strengthen the immune system’s ability to fight cancer,” explains Rice. “But what makes Surge’s solution different is that it’s applied during surgery as opposed to other immunotherapies that are delivered weeks before or weeks after surgery.”